$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns

$mrns Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000155837024007187 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$8.056M	$7.679M
YoY Change	32.48%	-26.02%
Cost Of Revenue	$735.0K	$756.0K
YoY Change	90.41%	266.99%
Gross Profit	$7.321M	$6.923M
YoY Change	28.55%	-31.95%
Gross Profit Margin	90.88%	90.15%
Selling, General & Admin	$16.71M	$18.63M
YoY Change	6.28%	22.51%
% of Gross Profit	228.25%	269.05%
Research & Development	$20.90M	$24.12M
YoY Change	-2.41%	-13.66%
% of Gross Profit	285.44%	348.37%
Depreciation & Amortization	$140.0K	$131.0K
YoY Change	10.24%	-16.56%
% of Gross Profit	1.91%	1.89%
Operating Expenses	$37.61M	$42.74M
YoY Change	1.27%	-0.91%
Operating Profit	-$32.24M	-$35.82M
YoY Change	2.54%	8.67%
Interest Expense	-$3.508M	$4.346M
YoY Change	-183.37%	4.8%
% of Operating Profit
Other Income/Expense, Net	-$84.00K	$36.00K
YoY Change	-278.72%	-2.7%
Pretax Income	-$35.83M	-$38.67M
YoY Change	7.04%	11.34%
Income Tax
% Of Pretax Income
Net Earnings	-$35.83M	-$38.70M
YoY Change	12.19%	11.53%
Net Earnings / Revenue	-444.74%	-503.97%
Basic Earnings Per Share	-$0.63	-$0.68
Diluted Earnings Per Share	-$0.63	-$0.68
COMMON SHARES
Basic Shares Outstanding	54.93M	54.64M
Diluted Shares Outstanding	57.06M	56.85M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$64.68M	$113.3M
YoY Change	-63.11%	-43.15%
Cash & Equivalents	$64.70M	$104.3M
Short-Term Investments		$9.000M
Other Short-Term Assets	$8.898M	$8.727M
YoY Change	-21.71%	-3.72%
Inventory	$4.873M	$5.783M
Prepaid Expenses
Receivables	$3.435M	$3.513M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$81.88M	$131.3M
YoY Change	-57.92%	-40.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.720M	$3.735M
YoY Change	-5.54%	-7.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.481M	$2.339M
YoY Change	-44.18%	-16.01%
Total Long-Term Assets	$5.201M	$6.074M
YoY Change	-21.09%	-10.96%
TOTAL ASSETS
Total Short-Term Assets	$81.88M	$131.3M
Total Long-Term Assets	$5.201M	$6.074M
Total Assets	$87.08M	$137.4M
YoY Change	-56.72%	-39.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.237M	$6.125M
YoY Change	170.94%	37.15%
Accrued Expenses	$15.23M	$18.72M
YoY Change	-14.89%	19.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.55M	$15.40M
YoY Change	200.0%
Total Short-Term Liabilities	$35.87M	$42.76M
YoY Change	40.09%	98.75%
LONG-TERM LIABILITIES
Long-Term Debt	$45.08M	$58.07M
YoY Change	-33.85%	-18.78%
Other Long-Term Liabilities	$53.49M	$52.95M
YoY Change	6.71%	8.69%
Total Long-Term Liabilities	$98.56M	$111.0M
YoY Change	-16.66%	-7.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.87M	$42.76M
Total Long-Term Liabilities	$98.56M	$111.0M
Total Liabilities	$134.4M	$153.8M
YoY Change	-6.56%	8.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$646.4M	-$610.6M
YoY Change	30.01%	31.23%
Common Stock	$55.00K	$55.00K
YoY Change	7.84%	10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$47.35M	-$16.43M
YoY Change
Total Liabilities & Shareholders Equity	$87.08M	$137.4M
YoY Change	-56.72%	-39.44%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$35.83M	-$38.70M
YoY Change	12.19%	11.53%
Depreciation, Depletion And Amortization	$140.0K	$131.0K
YoY Change	10.24%	-16.56%
Cash From Operating Activities	-$30.84M	-$37.46M
YoY Change	26.62%	-9.68%
INVESTING ACTIVITIES
Capital Expenditures	$38.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$9.000M	$20.89M
YoY Change	79.86%	-140.17%
Cash From Investing Activities	$8.962M	$20.89M
YoY Change	79.1%	-140.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-17.70M	257.0K
YoY Change	-7567.51%	-247.7%
NET CHANGE
Cash From Operating Activities	-30.84M	-37.46M
Cash From Investing Activities	8.962M	20.89M
Cash From Financing Activities	-17.70M	257.0K
Net Change In Cash	-39.58M	-16.32M
YoY Change	107.03%	-82.57%
FREE CASH FLOW
Cash From Operating Activities	-$30.84M	-$37.46M
Capital Expenditures	$38.00K
Free Cash Flow	-$30.88M
YoY Change	26.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesNoncurrent
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001267813
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesNoncurrent
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-36576
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	MARINUS PHARMACEUTICALS, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0198082
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Radnor Corporate Center, Suite 500
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	100 Matsonford Rd
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Radnor
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19087
CY2024Q1	dei	City Area Code CityAreaCode	484
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	801-4670
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	MRNS
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54933774
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104253000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120572000
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	9000000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29716000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3513000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3799000
CY2024Q1	us-gaap	Inventory Net InventoryNet	5783000
CY2023Q4	us-gaap	Inventory Net InventoryNet	2413000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8727000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8746000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	131276000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	165246000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3735000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3843000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2339000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1819000
CY2024Q1	us-gaap	Assets Assets	137350000
CY2023Q4	us-gaap	Assets Assets	170908000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6125000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4003000
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	15401000
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	11551000
CY2024Q1	mrns	Revenue Interest Financing Payable Current RevenueInterestFinancingPayableCurrent	2511000
CY2023Q4	mrns	Revenue Interest Financing Payable Current RevenueInterestFinancingPayableCurrent	2211000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18721000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22859000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	42758000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40624000
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	58072000
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	61423000
CY2024Q1	mrns	Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent	34642000
CY2023Q4	mrns	Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent	33766000
CY2024Q1	mrns	Contract With Customer Contract Liability Net Of Contract Asset ContractWithCustomerContractLiabilityNetOfContractAsset	17730000
CY2023Q4	mrns	Contract With Customer Contract Liability Net Of Contract Asset ContractWithCustomerContractLiabilityNetOfContractAsset	17545000
CY2024Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	582000
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	785000
CY2024Q1	us-gaap	Liabilities Liabilities	153784000
CY2023Q4	us-gaap	Liabilities Liabilities	154143000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54938349
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54931042
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54585428
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54578121
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	55000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	55000
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	594106000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	588656000
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7307
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7307
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-610595000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-571926000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-16434000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	16765000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137350000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	170908000
CY2024Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	152000
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	7048000
CY2024Q1	us-gaap	Revenues Revenues	7679000
CY2023Q1	us-gaap	Revenues Revenues	10380000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24118000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27933000
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18626000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15204000
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	43500000
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	43343000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-35821000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-32963000
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1462000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2343000
CY2024Q1	us-gaap	Interest Expense InterestExpense	4346000
CY2023Q1	us-gaap	Interest Expense InterestExpense	4147000
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	36000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37000
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-38669000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34730000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56851811
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56851811
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51769685
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51769685
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	20000
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	74000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38649000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34656000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-38669000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-34730000
CY2024Q1	us-gaap	Depreciation Depreciation	131000
CY2023Q1	us-gaap	Depreciation Depreciation	157000
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	609000
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	480000
CY2024Q1	mrns	Accretion Of Revenue Interest Financing Debt AccretionOfRevenueInterestFinancingDebt	1065000
CY2023Q1	mrns	Accretion Of Revenue Interest Financing Debt AccretionOfRevenueInterestFinancingDebt	1440000
CY2024Q1	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	149000
CY2023Q1	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	228000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5193000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3741000
CY2024Q1	mrns	Increase Decrease Amortization Of Net Contract Asset Liability IncreaseDecreaseAmortizationOfNetContractAssetLiability	337000
CY2023Q1	mrns	Increase Decrease Amortization Of Net Contract Asset Liability IncreaseDecreaseAmortizationOfNetContractAssetLiability	413000
CY2024Q1	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	47000
CY2023Q1	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	53000
CY2024Q1	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	224000
CY2023Q1	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	96000
CY2023Q1	mrns	Fixed Assets Written Off FixedAssetsWrittenOff	62000
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-522000
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-544000
CY2024Q1	mrns	Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable	3833000
CY2023Q1	mrns	Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable	8963000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2264000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3717000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37461000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41478000
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	20885000
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	51995000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20885000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51995000
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	257000
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-174000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	257000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-174000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16319000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-93647000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120572000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	240551000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104253000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	85085000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	16765000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146904000
CY2024Q1	mrns	Unrealized Gain Loss On Short Term Investments Cash Flow UnrealizedGainLossOnShortTermInvestmentsCashFlow	20000
CY2023Q1	mrns	Unrealized Gain Loss On Short Term Investments Cash Flow UnrealizedGainLossOnShortTermInvestmentsCashFlow	74000
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	2671000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	2156000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	116000000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3741000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	74000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-34730000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5193000
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	257000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	20000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-38669000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-16434000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-38700000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-610600000
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	113300000
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p>
CY2024Q1	mrns	Number Of Customers NumberOfCustomers	3
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2024Q1	mrns	Number Of Customers NumberOfCustomers	3
CY2024Q1	mrns	Trade Receivable Payment Term TradeReceivablePaymentTerm	P30D
CY2024Q1	us-gaap	Cash Cash	1400000
CY2024Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	102900000
CY2023Q4	us-gaap	Cash Cash	1300000
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	119300000
CY2024Q1	us-gaap	Interest Receivable InterestReceivable	100000
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	200000
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	9000000
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	155000
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	155000
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	9000000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	29736000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	169000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	189000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	29716000
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3600000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	436000
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1591000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1075000
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	592000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	902000
CY2024Q1	us-gaap	Inventory Net InventoryNet	5783000
CY2023Q4	us-gaap	Inventory Net InventoryNet	2413000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2830000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7746000
CY2024Q1	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	5694000
CY2023Q4	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	4701000
CY2024Q1	mrns	Accrued License Agreement Payment AccruedLicenseAgreementPayment	2000000
CY2023Q4	mrns	Accrued License Agreement Payment AccruedLicenseAgreementPayment	4000000
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1669000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1236000
CY2024Q1	mrns	Selling And Commercial Liabilities Current SellingAndCommercialLiabilitiesCurrent	4502000
CY2023Q4	mrns	Selling And Commercial Liabilities Current SellingAndCommercialLiabilitiesCurrent	3901000
CY2024Q1	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	1306000
CY2023Q4	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	774000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	720000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	501000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18721000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22859000
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10964919
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9545512
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5193000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3741000
CY2022Q4	mrns	Maximum Percentage Of Beneficial Ownership For Exercise Of Pre Funded Warrants MaximumPercentageOfBeneficialOwnershipForExerciseOfPreFundedWarrants	0.0999
CY2022Q4	mrns	Maximum Percentage Increase Or Decrease Of Beneficial Ownership For Exercise Of Pre Funded Warrants MaximumPercentageIncreaseOrDecreaseOfBeneficialOwnershipForExerciseOfPreFundedWarrants	0.1999
CY2024Q1	mrns	Maximum Shares Available For Issuance Value Equity Distribution Agreement MaximumSharesAvailableForIssuanceValueEquityDistributionAgreement	75000000
CY2024Q1	mrns	Equity Distribution Agreement Commission Percentage Maximum EquityDistributionAgreementCommissionPercentageMaximum	0.030
CY2023Q1	mrns	Stock Issued During Period Shares Equity Distribution Agreement StockIssuedDuringPeriodSharesEquityDistributionAgreement	0
CY2024Q1	mrns	Stock Issued During Period Shares Equity Distribution Agreement StockIssuedDuringPeriodSharesEquityDistributionAgreement	0
CY2024Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P78M
CY2024Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P18M
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1500000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1000000.0
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1900000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1400000
CY2024Q1	us-gaap	Lease Cost LeaseCost	300000
CY2023Q1	us-gaap	Lease Cost LeaseCost	100000
CY2024Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.110
CY2024Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1073000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	955000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2028000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	140000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1888000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1306000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	582000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1888000
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000.0
CY2024Q1	mrns	Debt Instrument Minimum Liquidity Covenant DebtInstrumentMinimumLiquidityCovenant	15000000.0
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000
CY2024Q1	mrns	Contractual Term Loan Exit Fees ContractualTermLoanExitFees	2003000
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3530000
CY2024Q1	us-gaap	Notes Payable NotesPayable	73473000
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	15401000
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	58072000
CY2024Q1	us-gaap	Notes Payable NotesPayable	73473000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	11250000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	15000000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	48750000
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	75000000
CY2024Q1	mrns	Revenue Interest Financing Agreement Issuance Costs RevenueInterestFinancingAgreementIssuanceCosts	2600000
CY2024Q1	mrns	Revenue Interest Financing Agreement Estimated Effective Annual Interest Rate RevenueInterestFinancingAgreementEstimatedEffectiveAnnualInterestRate	0.18
CY2022Q4	mrns	Revenue Interest Financing Agreements RevenueInterestFinancingAgreements	30877000
CY2023Q1	mrns	Revenue Interest Financing Agreement Non Cash Interest Income Expense RevenueInterestFinancingAgreementNonCashInterestIncomeExpense	1440000
CY2023Q1	mrns	Revenue Interest Financing Agreement Amortization Of Debt Discount RevenueInterestFinancingAgreementAmortizationOfDebtDiscount	71000
CY2023Q1	mrns	Revenue Interest Financing Agreement Payments RevenueInterestFinancingAgreementPayments	-174000
CY2023Q1	mrns	Revenue Interest Financing Agreements RevenueInterestFinancingAgreements	32214000
CY2023Q1	mrns	Revenue Interest Financing Payable Current RevenueInterestFinancingPayableCurrent	1321000
CY2023Q1	mrns	Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent	30893000
CY2023Q1	mrns	Revenue Interest Financing Agreements RevenueInterestFinancingAgreements	32214000
CY2023Q4	mrns	Revenue Interest Financing Agreements RevenueInterestFinancingAgreements	35977000
CY2024Q1	mrns	Revenue Interest Financing Agreement Non Cash Interest Income Expense RevenueInterestFinancingAgreementNonCashInterestIncomeExpense	1556000
CY2024Q1	mrns	Revenue Interest Financing Agreement Amortization Of Debt Discount RevenueInterestFinancingAgreementAmortizationOfDebtDiscount	111000
CY2024Q1	mrns	Revenue Interest Financing Agreement Payments RevenueInterestFinancingAgreementPayments	-491000
CY2024Q1	mrns	Revenue Interest Financing Agreements RevenueInterestFinancingAgreements	37153000
CY2024Q1	mrns	Revenue Interest Financing Payable Current RevenueInterestFinancingPayableCurrent	2511000
CY2024Q1	mrns	Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent	34642000
CY2024Q1	mrns	Revenue Interest Financing Agreements RevenueInterestFinancingAgreements	37153000
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	400000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
mrns-20240331_def.xml	Edgar Link	unprocessable
0001558370-24-007187-index-headers.html	Edgar Link	pending
0001558370-24-007187-index.html	Edgar Link	pending
0001558370-24-007187.txt	Edgar Link	pending
0001558370-24-007187-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrns-20240331.xsd	Edgar Link	pending
mrns-20240331x10q.htm	Edgar Link	pending
mrns-20240331x10q004.jpg	Edgar Link	pending
mrns-20240331x10q007.jpg	Edgar Link	pending
mrns-20240331xex31d1.htm	Edgar Link	pending
mrns-20240331xex31d2.htm	Edgar Link	pending
mrns-20240331xex32d1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
mrns-20240331_cal.xml	Edgar Link	unprocessable
mrns-20240331_pre.xml	Edgar Link	unprocessable
mrns-20240331_lab.xml	Edgar Link	unprocessable
mrns-20240331x10q_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns

2024 Q2 Form 10-Q Financial Statement

#000155837024007187 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNS MARINUS PHARMACEUTICALS, INC. Stock $mrns

2024 Q2 Form 10-Q Financial Statement

#000155837024007187 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns